Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q3 2024 · 10-Q
Revenue—
Net Income-$3.30M-$3.30MN/M vs Q3 2023 EPS Diluted-$0.01-$0.01— vs Q3 2023 Operating Income-$3,280,757N/M Operating Cash Flowderived-$143,198N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 19, 2024 · 50 d after period end